Evidence-Based Complementary and Alternative Medicine Exploring Active Components and Mechanism of Jinhua Qinggan Granules in Treatment of COVID-19 Based on Virus-Host Interaction

This study aimed at exploring the active components and mechanisms of Jinhua Qinggan granules (JQG) in the prevention and treatment of coronavirus disease 2019 (COVID-19) using network pharmacology and molecular docking technology. These efforts were accomplished by employing the holistic approach of traditional Chinese medicine (TCM) and considering the virus-host interaction consisting of viral characteristics, the entry pathway into the host, and the resulting immune response. The chemical constituents and molecular targets of the 12 herbs from JQG were obtained using the TCM Systems Pharmacology database and analysis platform. UniProt was used to search for genes corresponding to JQG protein targets and Cytoscape 3.7.2 to construct the component-target (gene) network. Database for Annotation, Visualization and Integrated Discovery was used to perform enrichment analysis of gene ontology functions and the Kyoto Encyclopedia of Genes and Genomes pathways to predict the mechanism of action. The components ranked high in the network, and the major active components of the principal medicines, based on published literature, were docked with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3CL hydrolase, SARS-CoV-2 spike glycoprotein (S protein), angiotensin conversion enzyme II (ACE2), and suppressor of cytokine signaling 1 (SOCS1). Visualization analysis demonstrated that the core active components of JQG had a strong affinity for SARS-CoV-2 3CL hydrolase, SARS-CoV-2 S protein, ACE2, and SOCS1. These data imply that the potential active components of JQG may act on multiple signaling pathways by binding to targets such as SARS-CoV-2 3CL hydrolase, S protein, ACE2, and SOCS1, thereby inhibiting virus replication and targeting cell binding, reducing host inflammation, and activating antiviral immunity to a certain extent.